Regina Elena National Cancer Institute

medical research institute in Italy
rdfs:label
"Regina Elena National Cancer Institute"@en
skos:altLabel
"IRCCS Regina Elena National Cancer Institute"@en
"Regina Elena Cancer Institute"@en
"Regina Elena Institute"@en
"Regina Elena Institute for Cancer Research"@en
schema:description
"medical research institute in Italy"@en
schema:dateModified "2025-07-14T14:31:56+00:00"^^xsd:dateTime
schema:version 2379528091
wikibase:identifiers 6
wikibase:sitelinks 0
wikibase:statements 10
p:P1015 wd:statement/Q69734359-9a7587b4-402a-c856-61a5-0be78e402bfd
p:P13591 wd:statement/Q69734359-07E4B486-6406-41FA-BE6C-078F1C89AD2C
p:P138 wd:statement/Q69734359-47a5933f-4916-fb1d-a535-b7e7766981bd
p:P17 wd:statement/Q69734359-980bbeb7-4bd0-ce53-4016-9fd84b5aab53
p:P214 wd:statement/Q69734359-5e7b3840-418d-b91d-b639-912ba34b07a1
p:P244 wd:statement/Q69734359-5bde51ef-42da-322f-bb2f-11ae12fd7c3d
p:P31 wd:statement/Q69734359-3a989672-4a37-ae86-b106-68756a1db6dd
p:P3500 wd:statement/Q69734359-E8573DE8-1D17-4544-8A8A-5EE0AF39FA82
p:P691 wd:statement/Q69734359-AFFACFF2-179E-406F-84B6-91D8266AFB80
p:P749 wd:statement/Q69734359-a689fe74-4286-2291-4436-77efae633e0f
p:direct-normalized/P1015 <https://livedata.bibsys.no/authority/90666820>
p:direct-normalized/P214 <http://viaf.org/viaf/122388055>
p:direct-normalized/P244 <http://id.loc.gov/authorities/names/no2009097202>
wdt:P1015 "90666820"
wdt:P13591 "group/10204e44-71c9-4bb9-b8f0-c74bd20b7360"
wdt:P138 wd:Q181530
wdt:P17 wd:Q38
wdt:P214 "122388055"
wdt:P244 "no2009097202"
wdt:P31 wd:Q66737615
wdt:P3500 "18658"
wdt:P691 "kn20091120015"
wdt:P749 wd:Q30281366

Inverse relations

[ .. ] → p:statement/P108 → Regina Elena National Cancer Institute

<http://www.wikidata.org/entity/statement/Q56615917-673E5C55-C55D-4EA9-8AB3-689A71E19C51>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q56451561-D2716169-D8A8-4BCD-A067-376F53C68411>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q42400581-D0A4AE9E-6D56-4261-9452-E2A752BF3EAB>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q55381521-3A1D5D17-14A9-4569-BA46-D6DD579EC8A7>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q98162941-01D5BCC7-1892-4609-B8EF-993CAAC5F51E>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q56615917-24E7059F-1E17-40D5-AA25-5C06D6D6111C>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q42174925-9D9E8B4F-8B04-4978-8FD4-818A5E03A24A>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q93167044-63DDBD1A-5505-4568-943A-6ED376094219>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q55381521-E47F45E5-2754-45F3-B2C1-1601842C85BB>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q56395065-28CD5F98-92D1-4C7A-BAF4-A337C13ABE9F>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q56420560-3EBDA7BF-C453-47D3-9B8C-C431CFACE684>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q42773255-A69C445C-F02A-4FE7-B20D-52DE1E681AE9>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q42695894-45CDC7CE-9E01-496B-8B6A-2DD2CB3F0FC3>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q56155500-ED41FFB1-8403-475B-BF32-97B393CD0FFA>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q42220790-2E3E9986-8D8F-4E16-97A5-730576EF215B>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q98776432-21764175-0768-4B91-9C97-B7DE2351C720>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q56615937-D5A4DCB3-51DB-4137-90EA-E7FDD749FCB6>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q55381521-36815261-C54B-43CA-ACBE-7A201BE91C46>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q55763061-1CE814C0-F709-4857-95A6-560E579D3465>wikibase:BestRank <http://www.wikidata.org/entity/statement/Q55457832-244FE454-D3A6-4186-BBAB-E44EC013A476>wikibase:BestRank ... show all 177

[ .. ] → wdt:P6153 → Regina Elena National Cancer Institute

A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC) An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients Platine, Avastin and OLAparib in 1st Line Quality of Awakening and Impact on Cognitive Function After Administration of Sugammadex in Robotic Radical Cystectomy Recovery From Anesthesia After Robotic Assisted Radical Cystectomy Sevoflurane Protective Effect on Ischemia Reperfusion Injury in Microvascular Surgery Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab ... show all 24

[ .. ] → wdt:P69 → Regina Elena National Cancer Institute

[ .. ] → wdt:P355 → Regina Elena National Cancer Institute

Download as: